Myovant Sciences Ltd
NYSE:MYOV
Myovant Sciences Ltd
Income from Continuing Operations
Myovant Sciences Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Myovant Sciences Ltd
NYSE:MYOV
|
Income from Continuing Operations
-$183.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Income from Continuing Operations
-$151.1m
|
CAGR 3-Years
-142%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Income from Continuing Operations
-$208.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Income from Continuing Operations
-$168.2m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Income from Continuing Operations
-£55.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Income from Continuing Operations
£30.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
See Also
What is Myovant Sciences Ltd's Income from Continuing Operations?
Income from Continuing Operations
-183.8m
USD
Based on the financial report for Dec 31, 2022, Myovant Sciences Ltd's Income from Continuing Operations amounts to -183.8m USD.
What is Myovant Sciences Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-10%
Over the last year, the Income from Continuing Operations growth was 19%. The average annual Income from Continuing Operations growth rates for Myovant Sciences Ltd have been 15% over the past three years , -10% over the past five years .